Three abstracts presenting data from the study have been selected for poster presentations
TAMPA, Fla., April 12, 2016 – DYSIS Medical, a leading medical device company active in women’s health, announced today that three abstract submissions to the 2016 Annual Meeting of the American Society for Colposcopy and Cervical Pathology (ASCCP) have been accepted for poster presentations. The abstracts summarize initial findings from the ongoing 11,000-patient IMproved PRactice Outcomes and Value Excellence in Colposcopy (IMPROVE-COLPO) study and will be presented at the meeting to begin April 13, in New Orleans, LA. During the meeting, DYSIS Medical will also showcase its advanced cervical imaging system.
More than 12,000 U.S. women are diagnosed with cervical cancer annually and 4,300 die from the disease. Colposcopy, which can be very subjective, is the diagnostic procedure performed after an abnormal Pap smear to detect precancerous areas. The objective of the IMPROVE-COLPO study, which is the largest U.S. colposcopy community study to date, is to measure outcome improvements with the DYSIS Advanced Cervical Imaging System compared to standard colposcopy.
“Cervical cancer is preventable with early detection, and we are very excited to be at the forefront of the technology that can enhance a doctor’s ability to diagnose and manage cervical neoplasia, and ultimately to prevent cervical cancer,” said DYSIS Medical’s Clinical Manager, Dr. Manolis Papagiannakis. “The DYSISmap and the documentation images can add real value to doctors managing their patients’ health, and we are looking forward to sharing some of the initial findings from the IMPROVE-COLPO study with ASCCP Annual Meeting attendees.”
“The DYSIS advanced cervical imaging system has brought real value to my practice by helping me identify lesions not recognized with standard colposcopy, and to also manage young women more conservatively,” stated Dr. Aarathi Cholkeri-Singh, one of the principal investigators in the IMPROVE-COLPO study. “The high resolution images, electronic record documentation and ability to share the DYSISmap with patients has made a difference in ensuring that my patients understand their condition and are compliant to my follow-up care plan.”
About DYSIS Medical
DYSIS Medical has its global headquarters in Edinburgh and US Headquarters in Tampa, FL. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit: www.dysismedical.com or call 844-DYSISMED.
About the DYSIS colposcope
The DYSIS colposcope differs from traditional colposcopes by measuring the cervical epithelium automatically using Dynamic Spectral Imaging and producing a map of the cervix, which assists the clinician with assessing the cervix, identifying biopsy locations and performing treatment if needed.
About cervical cancer
Worldwide, cervical cancer is the fourth most common cancer for women and the seventh most common cancer overall. While it is the only entirely preventable cancer, approximately half a million women are diagnosed with the disease every year.